Genex Co., Ltd. Announcement of company exhibition at the 23rd Annual Meeting of the Japanese Mitochondrial Society

Genex Co., Ltd. press release (2024.11.07) Genex Co., Ltd. Announcement of 23rd Japanese Mitochondrial Society Annual Meeting Corporate Exhibition Exhibition Genex Co., Ltd. will hold a corporate exhibition at the 23rd Annual Meeting of the Japanese Mitochondrial Society, which will be held at Juntendo University Hongo Campus (Bunkyo-ku, Tokyo) for three days from November 21st (Thursday) to 23rd (Saturday). We will exhibit. Genex Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director: Ken Yagi, hereinafter referred to as “Genex” or the “Company”) will be hosting Juntendo for three days from November 21st (Thursday) to November 23rd (Saturday). We will be exhibiting at the 23rd Annual Meeting of the Japanese Mitochondrial Society, which will be held at the University of Hongo Campus (Bunkyo-ku, Tokyo). Image
URL: https://prcdn.freetls.fastly.net/release_image/55846/9/55846-9-f952362456c9a3ef82e970810adc389d-1000×183.png

Background/purpose In response to the fact that “mitochondrial disease gene panel testing,” which allows for the comprehensive investigation of the genes responsible for mitochondrial diseases, which are designated intractable diseases, will be covered by insurance in November 2023, we will begin conducting tests at Juntendo University from December 2023. We provide analysis software for mitochondrial disease gene panel testing. This software was developed by applying the experience and knowledge gained from providing genome testing services to general consumers since 2022, and is based on the standards specified by Juntendo University from the vast amount of data generated by next-generation sequencers. Extracts detection candidate variants (*) that meet the criteria and creates a draft version of the test result report. Juntendo University then processes the results into official test results after checking with a doctor and returns them to the medical institution that requested the test. Mitochondrial dysfunction causes various organ disorders, so doctors and researchers involved in the treatment and research of many diseases such as nerve and muscle diseases, inborn errors of metabolism, diabetes, kidney diseases, liver diseases, heart diseases, and ophthalmological diseases, We view this meeting, which has a wide range of cross-disciplinary participants, as an opportunity to introduce analysis software and genome testing services for medical institutions. Please feel free to visit our booth. *Variant: A concept that represents differences in the base sequence of DNA. There are various types, including SNPs (single nucleotide polymorphisms) that represent differences in one location, indels that represent insertions or deletions in base sequences, and the number of times the same sequence is repeated. Event overview
https://prcdn.freetls.fastly.net/release_image/55846/9/55846-9-e3d06a2ab64aa3b0189f440e4117b0be-759×458.png ▶️Name 23rd Annual Meeting of the Japanese Mitochondrial Society https://23jmit.jp/ ▶️Purpose/significance We are planning a symposium with the theme of “The bridge between basic and clinical science created by mitochondria” with the aim of deepening mutual
understanding between specialized researchers and medical
practitioners, as well as providing a place for both parties to present their research. We aim to deepen clinical integration. Chemical research targeting mitochondria is expected to further develop due to the discovery of new biological roles in recent years and the involvement of mitochondrial dysfunction in many diseases. ▶️Event schedule Thursday, November 21st to Saturday, November 23rd ▶️Venue Juntendo University Hongo Campus (2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421) https://www.juntendo.ac.jp/access/ ▶️Holding format Hybrid event ▶️Great Chairman Yasushi Okazaki (Director, Research Center for Diagnosis and Treatment of Intractable Diseases, Juntendo University/Professor, Department of Diagnosis and Treatment of Intractable Diseases, Graduate School of Medicine)
https://research-center.juntendo.ac.jp/nanbyo/about/ ▶️Register for participation Registration period: Until Thursday, November 14, 2024 https://yocto.ibmd.jp/23jmit/ Supplementary material Past press leases related to this matter can be found below. December 11, 2023: “Start providing analysis software for gene panel testing for incurable diseases to Juntendo University”
https://genex.co.jp/pdf/press20231211.pdf About Genex Our main shareholders include Monex Group Co., Ltd., Towns Co., Ltd., Sugi Pharmacy Co., Ltd., and Kaken Pharmaceutical Co., Ltd., which was established in August 2019 with the aim of improving the quality of health management based on data through genome testing services. This is a venture company. As Japan’s only private company (*) capable of whole-genome and whole-exome testing, we provide genome testing services to general consumers.In addition, as part of our joint research project in the rare disease field, we are engaged in the elucidation and diagnosis of mitochondrial diseases, which are designated as intractable diseases. In addition to participating in multi-institutional joint research with Saitama Medical University, Chiba Children’s Hospital, and Juntendo University aiming to develop treatments, we also provide agency services and consulting related to the acquisition and management of whole genome information. *As of October 1, 2024 (according to our research) Please see the URL below for details. Genex HP: https://genex.co.jp/ Genex Official X: https://x.com/genex_jp *Product names and service names in this text are trademarks or registered trademarks of each company.